Nutex Health, Inc. cash flow to debt ratio of 70.61% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Nutex Health, Inc.'s free cash flow has increased 1.08K% from $20.85M last year to $245.60M, signaling increasing performance

Nutex Health, Inc.'s debt to equity ratio is 0.88, which means that the company's assets are unhealthy financed, signaling financial risk.

Nutex Health, Inc.'s debt has decreased relative to shareholder equity from 2.33 last year to 0.88 today, signaling strengthened financials

Nutex Health, Inc. has a net debt to EBITDA ratio of 0.58x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Nutex Health, Inc.'s interest coverage ratio of 18.42 indicates that earnings with good margin can cover interest payments on company debt

Nutex Health, Inc.'s profit margin has increased (95.45%) in the last year from 10.87% to 21.25%, signaling increasing performance

Nutex Health, Inc.'s short-term assets of $538.81M exceed its short-term liabilities of $157.91M

Nutex Health, Inc.'s return on assets of 18.65% is higher than the 5.00% threshold, indicating efficient asset utilization

Nutex Health, Inc.'s return on equity of 51.88%, is higher than 15.00%, indicating good performance

Nutex Health, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Nutex Health, Inc. has insufficient public price history to evaluate earnings stability.

Nutex Health, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Nutex Health, Inc. has a free cash flow yield of 18.07%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Nutex Health, Inc.'s yearly earnings has increased 35.67% since last year from $52.18M to $70.79M, signaling increasing performance

Nutex Health, Inc.'s yearly revenue has increased 82.36% since last year from $479.95M to $875.26M, signaling increasing performance

ROIC 33.39% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Nutex Health, Inc.'s 3-year revenue CAGR of 58.62% is positive, indicating growing revenue over the past 3 years

Nutex Health, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Nutex Health, Inc. has insufficient public price history to evaluate ROE consistency.

Nutex Health, Inc. is undervalued relative to its fair value price of 704.29 based on Discounted Cash Flow model

Nutex Health, Inc. has an earnings yield of 13.59%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Nutex Health, Inc. is undervalued relative to its fair value price of 320.32 based on EBITDA multiple model

Nutex Health, Inc. has an EV/EBITDA ratio of 5.30x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Nutex Health, Inc. has insufficient data to evaluate this check.

Nutex Health, Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Nutex Health, Inc. has a price-to-book ratio of 2.61x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Nutex Health, Inc. has a price-to-sales ratio of 1.56x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue